Introduction
Gene amplification is common in solid tumors and is associated with adverse prognosis, disease progression, and development of resistance to chemotherapy (Savelyeva and Schwab, 2001) . Amplification of N-Myc in neuroblastoma (Seeger et al., 1985; Rubie et al., 1997) and amplification of HER-2/Neu in breast cancer are associated with shortened survival (Slamon et al., 1987 (Slamon et al., , 1989 . Amplification of the DHFR gene enables cancer cells to acquire resistance to the chemotherapeutic agent, methotrexate (Savelyeva and Schwab, 2001 ). Breast cancer with HER-2/Neu amplification may exhibit a relative resistance to nonanthracycline-based therapy but display retained or increased sensitivity to anthracycline-based treatment (Muss et al., 1994; Paik et al., 1998; Thor et al., 1998) . Amplification of chromosome 17q11-12 involving the HER-2/Neu gene has been described in breast (Slamon et al., 1987) , ovarian (Slamon et al., 1989) , head and neck (Press et al., 1994) , prostate (Ross et al., 1997) , endometrial (Rolitsky et al., 1999) , gastric and esophageal cancers (Ishikawa et al., 1997; Nakajima et al., 1999; Nessling et al., 1998; Brien et al., 2000; Walch et al., 2000) . As is the case with gene amplification in general, an increase in the copy number of HER-2/Neu gene leads to overexpression of HER-2/Neu transcript and protein.
Retention of amplified sequences in cancer cells indicates evolutionary advantage conferred by these amplified genes. Gene amplification may involve variable amount of sequence. At one extreme, the amplified sequence involving N-Myc in some neuroblastoma cells is pruned to a very limited segment of which N-Myc may be the only contributing genetic element (Amler and Schwab, 1989) . On the other hand, amplification of chromosome 11q13 may involve large, discontinuous blocks of chromosomal DNA Szepetowski et al., 1993) . The extent of the sequence that is amplified appears to be distinct among various tumor types. The pattern of overexpression of genes from the amplified segment differs as well (Theillet et al., 1990; Proctor et al., 1991; Szepetowski et al., 1992; Roelofs et al., 1993; Bringuier et al., 1996) . This nonuniformity provides evidence that distinct gene(s) are targets of 11q13 amplification in various tumor types. Similar complexity has been described for amplification events involving 17q22-23. Several specific and independent amplification maxima from this region were identified in breast cancer cell lines and breast tumors (Barlund et al., 2000; Wu et al., 2000; Monni et al., 2001; Wu et al., 2001) .
The gene content of the HER-2/Neu amplified sequences has recently been elucidated. Multiple genes from the chromosomal segment containing HER-2/Neu gene are coamplified with HER-2/Neu (Kauraniemi et al., 2001; Luoh, 2002) . Interestingly, there is near perfect correlation between increased gene dosage and overexpression for these genes in breast cancer cell lines (Kauraniemi et al., 2001; Luoh, 2002) . This observation raises the intriguing possibility that overexpression of multiple coamplified genes, rather than amplification of HER-2/Neu alone, may contribute to the development and/or progression of breast cancer that carries 17q11-12 amplification. Moreover, these genes may serve as additional targets for therapy for this subset of breast cancer patients who have a more aggressive form of disease.
By extracting sequence information from public databases, we have constructed a contig in bacterial artificial chromosomes (BACs) that extends from HER-2/Neu to a phosphotidylinositol phosphate kinase (PIPK), Pip4k2b from 17q11-12. Initially known as Pip5k2b it is now reclassified as Pip4k2b (Rameh et al., 1997) . The importance of phosphoinositides (PI) as lipid signaling molecules in eukaryotic cells has been well characterized. A number of phosphotidylinositol phosphate kinases have been described that can phosphorylate different positions of the inositol ring leading to the formation of PIP 2 and PIP 3 that have various signaling functions (Fruman et al., 1998; Anderson et al., 1999) . Known PI-3-kinases and PI-4-kinases share sequence homology over distinct domains. Pip4k2b belongs to a novel family of PI-4-P 5-kinases, which do not share significant homology to other known protein or lipid kinases. PIPKs have been implicated in many important functions such as vesicular trafficking and cytoskeleton assembly . A role for PIPKs in cancer has not been previously reported.
In this study, we show that Pip4k2b is amplified and overexpressed in a subset of breast cancer cell lines. Amplification of Pip4k2b is associated with overexpression on the transcript and protein level. An increase in the gene copy number of Pip4k2b that is significantly more than that of HER-2/Neu has been observed in one primary breast tumor. Moreover, dual color fluorescence in situ hybridization (FISH) reveals that amplified Pip4k2b gene may exist in structure not accompanied by that of HER-2/Neu in ZR-75-30 breast cancer cell line. These studies suggest that Pip4k2b may fall on an amplification maximum distinct from that of HER-2/ Neu and serve as an independent target for amplification and selective retention. Overexpression of Pip4k2b in breast cancer cell lines confers proliferation advantage and promotes anchorage-independent growth. Pip4k2b may therefore play important roles in the development and/or progression of breast cancer.
Results
A 17q11-12 contig from HER-2/Neu to Pip4k2b
By extracting sequence information from the public databases, we assembled a contig in BACs that extended from Hs.374824 through the HER-2/Neu gene to a lipid kinase, Pip4k2b from chromosome 17q11-12 (Figure 1 ). Overlap was established based on identity of sequenced portions of different BACs. This was verified with multiple PCR assays using primers derived from the regions of overlap (data not shown). Dual color FISH using two differentially labeled BAC probes derived from this region revealed colocalization of hybridization signals in breast cancer cells (not shown). A similar contig using many of the BACs reported here has recently been reported by NCBI (NT_010755), in confirmation of our result. The whole region has been completely sequenced. The distance between Hs.374824 and HER-2/Neu is about 220 kb and that between HER-2/Neu and Pip4k2b is about 900 kb. Figure 1 Physical linkage of HER-2/Neu and Pip4k2b. A chromosomal segment from 17q11-12 extending from HER-2/ Neu to Pip4k2b was cloned in a set of overlapping BACs. A total of 13 BACs were used to assemble this contig. BAC #129 was partially sequenced (dotted lines). BAC #131, #906, #56, #386, #2206, #387 #62, #2019, #390, #94 and #58 were completely sequenced (thick solid lines). BAC #98 has its insert sequenced from both ends (thin line with circles at ends). The location and direction of transcription for Pip4k2b HER-2/Neu, and Hs.374824 are indicated. The direction of the centromere is towards the right. Since the assembly of this contig, the whole region has been sequenced. The coordinates for Pip4k2b HER-2/Neu, and Hs. Northern blotting analysis of total RNA isolated from representative breast cancer cell lines using the same Pip4k2b probe as above. The position of the 6.2 kb transcript from Pip4k2b is marked with an arrow. MCF-7/HER-2 is derived from parental MCF-7 cell line and overexpresses HER-2/Neu transcript as a result of transfection. The amount of RNA loaded for each sample on the gel is shown with ethidium bromide staining at the bottom. (c) Immunoblotting analysis of total cellular protein isolated from representative breast cancer cell lines using an affinity-purified antipeptide antiserum against Pip4k2b. The position of the 48 kDa Pip4k2b protein signal is marked with an arrow. Left: no expression is noted in parental MCF-7 or SKBR-3 cell lines. Signals with the predicted size are seen in MCF-7 and SKBR-3 cells transfected with a full-length Pip4k2b cDNA expression vector, that is, MCF-7::GFP-IRES-Pip4k2b and SKBR-3::GFP-IRES-Pip4k2b. Signals of appropriately increased molecular weight (B75 kDa) are seen in the SKBR-3 and MCF-7 cells that are trasnfected to express a GFP and Pip4k2b fusion protein, that is, MCF-7::GFP-Pip4k2b and SKBR-3::GFP-Pip4k2b. No signal is seen with preimmune serum (not shown). Right: Pip4k2b expression in a panel of breast cancer cell lines by immunoblotting with affinity-purified antibody with validated specificity In order to examine the expression of Pip4k2b protein in different breast cancer cell lines, we first evaluate the specificity of our affinity-purified antiserum. Parental MCF-7 and SKBR-3 cells display no amplification or expression of Pip4k2b gene. As expected, no Pip4k2b protein signal was seen. A predicted 48 kDa protein product was seen in the SKBR-3 and MCF-7 cells trasnfected with a full-length Pip4k2b cDNA expression vector, that is, MCF-7::GFP-IRES-Pip4k2b and SKBR-3::GFP-IRES-Pip4k2b (Figure 2c , left). A B75 kDa protein product, expected of a Pip4k2b and GFP fusion protein, was seen in the SKBR-3 and MCF-7 cells that were trasnfected to express a GFP and Pip4k2b fusion protein, that is, MCF-7::GFP-Pip4k2b and SKBR-3::GFP-Pip4k2b (Figure 2c , left).
Immunoblotting with this affinity-purified antipeptide antiserum with validated specificity showed that the 48kDa Pip4k2b protein was readily detectable in BT-474, ZR-75-30 and UACC-812 cells but not in several other breast cancer cell lines without gene amplification or overexpression (Figure 2c , right). The above study indicates that there is very good correlation between gene amplification and overexpression for Pip4k2b in breast cancer cell lines. Of note, overexpression of HER-2/Neu in MCF-7 cell line did not significantly alter the expression of Pip4k2b.
HER-2/Neu and Pip4k2b amplification -a dual color FISH study
We used dual color FISH study to examine the structure of HER-2/Neu and Pip4k2b amplified DNA in breast cancer cell lines. BACs #62, which contains a portion of the HER-2/Neu gene, and BAC #58, which contains the Pip4k2b gene in its entirety, were differentially labeled. These probes were then pooled and hybridized simultaneously to metaphase spreads of breast cancer cells. Appropriate filter setting was adjusted to visualize each hybridization signal either individually or together.
In ZR-75-30, all amplified HER-2/Neu signals (red) were accompanied by amplified Pip4k2b signals (green). Intriguingly, clusters of amplified Pip4k2b signals were observed without concomitant amplification of HER-2/ Neu ( Figure 3 ). These results indicate that Pip4k2b can be amplified and/or selectively retained independently from HER-2/Neu. In BT-474 cells, on the contrary, there is colocalization of hybridization signals from amplified Pip4k2b and HER-2/Neu genes (data not shown).
HER-2/Neu and Pip4k2b amplification -analysis of primary breast tumor samples
We then used Southern analysis to examine the amplification status of both HER-2/Neu and Pip4k2b genes in primary breast tumor samples. DNA samples from 12 randomly selected primary breast tumors were analysed. Three probes were used -HER-2/Neu, Hs.374824, and Pip4k2b Hs.374824 is located on the telomeric side of HER-2/Neu gene while Pip4k2b is on the centromeric side ( Figure 1 ). As can be seen in Figure 4 , samples #1,#3, #6, and #12 had an increase in the copy number for HER-2/Neu and Hs.374824genes. Out of these four, only samples #3 and #12 showed a parallel increase in the copy number of the Pip4k2b gene. Most notably, there was an increase in the gene copy number of Pip4k2b in sample #5 without significant increase for either HER-2/Neu or Hs.374824 gene. The latter indicates that Pip4k2b may constitute part of an amplification maximum whose increase in gene copy number and/or subsequent selective retention is not exclusively driven by HER-2/Neu.
Taken together, analysis of both breast cancer cell lines and primary breast tumor samples indicates that amplification and/or subsequent retention of amplified Pip4k2b can proceed independently of HER-2/Neu. This supports the notion that Pip4k2b may be an additional target for amplification that confers selection advantage from chromosome 17q11-12.
Forced expression of Pip4k2b protein confers proliferation advantage in breast cancer cells with or without HER-2/Neu amplification
To understand the functional outcome of Pip4k2b protein overexpression in breast cancer cells, breast cancer cell lines that stably overexpressed Pip4k2b protein were established by transfection of a Pip4k2b cDNA expression vector. Two breast cancer cell lines were studied -MCF-7 and SKBR-3. MCF-7 cells do not carry HER-2/Neu amplification whereas SKBR-3 cells have high level of amplification. Cells expressing both GFP and Pip4k2b protein were made via transfection with a bi-cistronic expression vector. Cells expressing GFP alone served as a control. FACS was performed to derive a homogeneous polyclonal population of transfectants that expressed GFP, which could function as a surrogate marker for Pip4k2b expression. The expression of Pip4k2b in stable transfectants was verified by Western blotting (Figure 2c, left) . These cells were maintained in a logarithmic phase of growth in G418.
The proliferation of different transfectants was then measured directly. A fixed number of transfectants were plated out on day 0 in duplicate. The cell number of one set of cells was counted on day 1 and that for the remaining set on day 3 for MCF-7 transfectants and day 5 for SKBR-3 transfectants, respectively. Growth rate was determined by the ratio of the cell number derived on day 3 or 5 over that on day 1. The average fold of increase was 4.49 for MCF-7::GFP cells and 6.06 for MCF-7::GFP-IRES-Pip4k2b cells, respectively. The difference in the fold of increase between MCF-7::GFP cells and MCF-7::GFP-IRES-Pip4k2b cells (mean difference ¼ 1.57) was statistically significant (paired t ¼ 3.12; df ¼ 14; and P ¼ 0.0075 ). The average fold of increase was 6.35 for SKBR-3::GFP cells and 8.28 for SKBR-3::GFP-IRES-Pip4k2b cells. The difference in the fold of increase between SKBR-3::GFP cells and SKBR-3::GFP-IRES-Pip4k2b cells (mean difference ¼ 1.92) was statistically significant as well (paired t ¼ 2.64; df ¼ 11; and P ¼ 0.023).
To corroborate the above observation, we used CellTiter assays (Promega) to measure the proliferation of MCF-7 and SKBR-3 transfectants, respectively. Replicate samples of different transfectants were plated at a fixed number in 96-well plates (n ¼ 8). Proliferation of plated cells was then serially determined at days 1, 3 and 5. For both MCF-7 and SKBR-3 cells, Pip4k2b transfectants displayed statistically increased proliferation compared with their GFP expressing control ( Figure 5 ). Taken together, the above shows that in the presence or absence of HER-2/Neu amplification, overexpression of Pip4k2b in breast cancer cells may confer proliferation advantage.
Forced expression of Pip4k2b protein causes morphological changes in MCF-7 cells
Expression of wild-type Pip4k2b in MCF-7 cells was associated with morphological changes (Figure 6 ). Forced expression of Pip4k2b protein promotes anchorage-independent growth in breast cancer cells with or without HER-2/Neu amplification MCF-7::GFP-IRES-Pip4k2b cells readily formed visible colonies in soft agar assays, which was not observed in MCF-7::GFP cells (Figure 7 , upper). SKBR-3::GFP cells could produce a small number of small colonies in soft agar. By contrast, SKBR-3 cells expressing Pip4k2b and GFP showed enhanced colony formation with an increase in both the number and size of colonies in soft agar (Figure 7 , lower). The above indicates that expression of Pip4k2b protein can promote anchorageindependent growth in breast cancer cells in the presence as well as the absence of HER-2/Neu amplification.
Discussion
Amplification and overexpression of HER-2/Neu protooncogene and its association with poor clinical outcome have been well established (Slamon et al., 1987 (Slamon et al., , 1989 Press et al., 1993; Seshadri et al., 1993; Ravdin and Chamness, 1995; Ross and Fletcher, 1999; Pauletti et al., 2000) . Overexpression of HER-2/Neu is thought to be responsible for many of the characteristics of breast cancer with HER-2/Neu amplification (Di Fiore et al., 1987; Hudziak et al., 1987; Chazin et al., 1992; Guy et al., 1992; Pietras et al., 1995) . Contribution from additional coamplified and overexpressed genes from 17q11-12 cannot be ruled out. The core region from 17q11-12 that is commonly amplified in breast cancer cell lines has recently been described (Kauraniemi et al., 2001; Luoh, 2002) . Intriguingly, there is a striking correlation between amplification and overexpression of genes neighboring HER-2/Neu from this region (Kauraniemi et al., 2001; Luoh, 2002) . Several of these genes likely have tumor-related functions and their roles in breast cancer development and/or progression are worthy of further study. Moreover, breast cancer with HER-2/Neu amplification is a more virulent disease. Current anti-HER-2/Neu-based therapy with Herceptin benefits only about half of the patients (Slamon et al., 2001) . Additional effective therapy is thus needed to battle this more aggressive form of breast cancer. Continued work, therefore, is necessary to assess whether other coamplified and overexpressed genes from the region may serve as rational targets for therapy.
We report in this study that Pip4k2b, a PIPK, is physically linked to HER-2/Neu from 17q11-12. Initially known as Pip5k2b it is now reclassified as Pip4k2b (Rameh et al., 1997) . Pip4k2b is amplified in a subset of breast cancer cells with HER-2/Neu amplification. Amplification is associated with overexpression on both RNA and protein levels. Interestingly, amplification and/or selective retention of Pip4k2b can occur independent of HER-2/Neu, indicating that Pip4k2b can be an additional target for amplification from 17q11-12. The retention of Pip4k2b amplified sequences indicates selection advantage conferred by an increase in the copy number of the Pip4k2b gene. In support of this notion, Pip4k2b amplification in breast cancer S-W Luoh et al overexpression of Pip4k2b gene in breast cancer cell lines can indeed increase proliferation rates and enhance anchorage-independent growth. This growth promoting function is observed in the presence as well as the absence of concurrent HER-2/Neu amplification. Our study therefore establishes an important functional role for Pip4k2b in the development and/or progression of breast cancer that carries 17q11-12 amplification and overexpression involving this gene.
In mammalian cells, two types of PIPKs have been characterized, type I and type II and each has three isoforms that are named a, b, and g (Fruman et al., 1998; Anderson et al., 1999) . The diversity of PIPKs allows them to use different substrates and to generate multiple signaling molecules. Although related in sequence, type I and type II PIPKs localize to different cellular compartments, have different substrate specificity and are functionally nonredundant (Homma et al., 1998; Kunz et al., 2000) . Initially identified as a PI-4-P 5-kinase, type II PIPK has been shown to be predominantly a 4-kinase (Rameh et al., 1997) . Type I PIPKs are dual specificity kinases and can phosphorylate both the 4-and 5-hydroxyls of the inositol ring (Rameh et al., 1997; Zhang et al., 1997; Tolias et al., 1998) . More recently, a novel type III PIPK, which is the mammalian homologue of the yeast Fab1, has been identified (Gary et al., 1998; McEwen et al., 1999; Sbrissa et al., 1999) .
In mammalian cells, type I PIPKs are found at the cell membrane, in the nucleus and Golgi. Type II PIPKs localize to the cytosol, the nucleus, the ER and the actin cytoskeleton but not primarily at the plasma membrane. Type I PIPKs have been implicated in secretion, vesicular trafficking, apoptosis, ion channel activity and regulation of actin assembly in eukaryotic cells (Hay et al., 1995; Shibasaki et al., 1997; Huang et al., 1998; Ishihara et al., 1998; Arneson et al., 1999; Mejillano et al., 2001) . The function of type II PIPKs is largely unknown. Recent report suggests a role for the type II PIPKs in calcium ion induced granule secretion in platelets (Rozenvayn and Flaumenhaft, 2001 ). Involvement of type II PIPK in aspects of tumor necrosis factor a-mediated signaling has been proposed (see below) (Castellino et al., 1997) . The roles of PI and PIPKs in nuclear PI signaling remain speculative at this point.
Recently the crystal structure of Pip4k2b has been solved (Rao et al., 1998) . The tertiary structure of Pip4k2b consists of two identical subunits that interact at the N terminus. The dimer is an elongated flat, disc like structure with clustering of charged amino acids on one surface. The charge and flatness suggest that it serves as an interface for membrane association via electrostatic interaction with the phospholipid headgroups. The N-terminal portion of Pip4k2b is required for its association with the p55 TNF receptor. The portion of the p55 TNF receptor that is required for this association is the juxta-membrane domain of the receptor (Castellino et al., 1997) . Many of the PI signaling enzymes directly interact with membrane receptors with the most notable ones being receptor tyrosine kinases. The functional significance of the association of Pip4k2b with p55 TNF receptor remains to be elucidated.
Amplification of the gene encoding the catalytic subunit of the PI-3-K has been reported in about 40% of ovarian cancer (Shayesteh et al., 1999) and non-smallcell lung cancer (Massion et al., 2002) . There is association between an increase in the gene copy number and the PI-3-K enzyme activity (Shayesteh et al., 1999) . In addition, AKT2, which is a downstream effector of PI-3-K, is amplified in ovarian and pancreatic cancers (Cheng et al., 1992; Bellacosa et al., 1995; Cheng et al., 1996) . A role of PIPK in cancer has not been reported in the past. We describe here for the first time that Pip4k2b is a target for amplification from 17q11-12. Moreover, overexpression of Pip4k2b is associated with a broad range of cancer-related functions such as morphological changes, increased proliferation and enhanced anchorage-independent growth. Our observations implicate Pip4k2b in the development and/or progression of a subset of breast cancer that carries its amplification.
In summary, we report amplification and overexpression of Pip4k2b in breast cancer. Pip4k2b is amplified in a subset of breast cancer with HER-2/Neu amplification but it can be a target for amplification and/or selective retention independent of HER-2/Neu. Overexpression of Pip4k2b in breast cancer cells leads to morphological change and enhances proliferation and anchorageindependent growth. Our study unravels unexpected genetic complexity and indicates gene(s) other than HER-2/Neu from 17q11-12 may confer selection advantage and serve as target(s) for amplification. Our study reveals that Pip4k2b may play important roles in the development and/or progression of breast cancer. Further study will focus on whether breast cancer with Pip4k2b amplification has distinct clinical behaviors and whether blockage of its activity is of therapeutic benefit in breast cancer with Pip4k2b amplification.
Materials and methods

BAC and plasmid constructs
BAC and plasmid clones used in this study were obtained from Research Genetics (Huntsville, AL, USA). The following BACs have been sequenced in their entirety: BAC#131 (Genbank accession number AC005288), BAC#906 (AC004408), BAC#56 (AC006441), BAC#62 (AC087491), BAC#2019 (AC040933), and BAC#390 (AC009283), BAC#58 (AC006449), BAC#2206 (AC091178), BAC#387 (AC090844) and BAC#386 (AC007901). The following BAC has been sequenced in draft: BAC#129 (AC021102). BAC#98 (AQ320284 and AQ320287) has been end sequenced. The identities and overlap of BACs were verified by PCR assays based upon available sequence information. Preparation of BAC DNA was performed with QIAGEN Plasmid Midi Kit (QIAGEN, Inc., Valencia, CA, USA) except that twice as much buffer was used in alkaline lysis.
Full-length cDNA of human Pip4k2b was derived from IMAGE clone #2412369. Sequence analysis of the insert of IMAGE #2412369 revealed that it contained the entire coding region of the Pip4k2b gene identical to that described in Genbank number U85245. Pip4k2b open reading frame was released as a SmaI and XhoI fragment and inserted into the Eco47III and XhoI sites of pIRES2-EGFP vector (BD Bioscience Clontech, Palo Alto, CA, USA) to make the GFP-IRES-Pip4k2b expression vector. The same SmaI and XhoI fragment was inserted into the ScaI and XhoI sites of pEGFP-C3 to make the GFP-Pip4k2b expression vector. The former will concurrently express full-length Pip4k2b protein and GFP from a bi-cistronic message. The latter will express Pip4k2b protein that is fused in frame, which is verified by sequencing, to the carboxyl terminus of GFP.
Hs.374824 is encoded by IMAGE #2156561 (Genbank number AF373101). Sequence analysis reveals that it encodes a protein that is evolutionarily conserved (S-W Luoh, unpublished observation). Both IMAGE #2412369 and #2156561 clones were obtained from Research Genetics.
Cell lines and cultures
The following breast cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA): BT-20, MB-MDA-468, MB-MDA-435, MB-MDA-453, MB-MDA-361, MCF-7, HBL-100, ZR-75-1, ZR-75-30, HCC-1954, SKBR-3, BT-474, T-47D, and UACC-812 . MCF-7/HER-2 is MCF-7 cell overexpressing a stably transfected full-length HER-2/Neu cDNA. All cells except UACC-812 are grown in RPMI supplemented with 10% fetal bovine serum at 371C in a humidified atmosphere with 5% CO 2 . UACC-812 is grown in L-15 medium supplemented with 10% fetal bovine serum without CO 2 .
Southern analysis
Genomic DNA was isolated from cell lines following proteinase K digestion, phenol-chloroform extraction and isopropanol precipitation. Genomic DNA from UACC-893 was obtained from the American Type Culture Collection (Manassas, VA, USA) directly. Breast tumor genomic DNA was a gift from Dennis Slamon at UCLA Medical Center. A measure of 10 mg of genomic DNA was digested with EcoRI, separated in agarose gel, and transferred to nylon membrane. Inserts from IMAGE clones #2412369 and #2156561 were used as probes. Membranes were hybridized with probes labeled with random hexamer priming, washed and subject to autoradiography backed with intensifying screens.
Northern analysis
Total RNA was isolated from breast cancer cell lines with TRIzol based upon the manufacturer's recommendation (Life Technologies, Gaithersburg, MD, USA). In all, 20 mg of total cellular RNA was denatured by heating in the presence of formamide, separated by electrophoresis in 1% agarose gel containing formaldehyde, transferred to nylon membranes, and hybridized with a 32 P-labeled Pip4k2b probe as described above. The intensity of the 28S and 18S rRNAs of each lane after ethidium bromide staining prior to transfer was used as loading control.
Protein isolation and Western analysis
Cultured cells were first washed twice with ice-cold phosphate buffered saline (pH 7.4). and then lysed on ice in a buffer containing 50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM NaF, 1 mM PMSF, 1 mM sodium vanadate, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin. After centrifugation in cold room at maximal speed for 30 min, supernatants were collected and stored in À801C until use. For Western blotting analysis, 20 mg of protein was separated on a 10% SDS-polyacrylamide gel and transferred onto Hybond ECL membranes (Amersham). These membranes were then blocked at room temperature with gentle rocking for 1 h with 5% w/v nonfat dry milk in 1 Â Tris-buffered saline and 0.05% Tween 20 (TBST). Affinity-purified antipeptide antiserum at appropriate dilution was incubated with the membranes in the presence of TBST with 5% w/v nonfat dry milk overnight at 41C with gentle rocking. After washing and incubation with secondary antibody, signals were detected using the LumiGLO reagents (Cell Signaling) and exposure to X-ray film (X-OMAT, Eastman Kodak Co.).
Antiserum and affinity purification
Rabbit polyclonal antibody was generated against an isoformspecific peptide derived from a nonhomologous region at the N-terminal portion of the human Pip4k2b protein. This region was chosen to minimize crossreactivity against other members of this family of lipid kinase (PIPKs). The peptide sequence is as follows: Ser-Ser-Asn-Cys-Thr-Ser-Thr-Thr-Ala-ValAla-Val-Ala-Pro-Leu-Ser-Ala-Ser-Lys. The internal cysteine residue was used for conjugation to Keyhole Limpet Hemocyanin carrier protein. Serial boosting was performed and the titer of antiserum monitored with ELISA. Rabbit antiserum was subsequently affinity purified using a column conjugated with the same peptide antigen used for immunization.
DNA transfection and establishment of polyclonal stable transfectants
Pip4k2b expression and control vectors were transfected into MCF-7 and SKBR-3 cell lines with TransIt-LT-1 reagent (PanVera) according to the manufacturer's recommendation. Cells were then selected in medium containing G418 (Life Technologies, Inc.) at 400 mg/mm (active form). Polyclonal G418-resistant cells were expanded and grown in logarithmic phase in medium containing G418 and split for passage when appropriate.
Flow cytometry and cell sorting
High GFP expressing transfected cells were sorted on a FACSVantaget SE (BD Biosciences, San Jose, CA, USA) equipped with a Spectra-Physics argon-ion laser emitting at 488 nm. GFP was detected in the FL1 channel with a 530 nm band-pass filter. Analysis was performed using CELLQuestt software (BD Biosciences, San Jose, CA, USA). Flow Cytometry (Coulter XL) analysis was used to monitor the percentage of cells that were expressing GFP with the FL-1 channel.
Cell proliferation assays
(1) Sorted SKBR-3 or MCF-7 transfectants were seeded in duplicate at a density of 50 000 per well in 12-well plates on day 0. Cells from one of the wells were harvested and counted manually with a counting chamber on day 1. Cells from the remaining wells were counted on day 3 for MCF-7 transfectants and day 5 for SKBR-3 transfectants, respectively. The fold increase for different transfectants was compared for each experiment. These experiments were repeated multiple times as indicated for both MCF-7 and SKBR-3 transfectants.
(2) Sorted SKBR-3 or MCF-7 transfectants were plated into flat-bottomed 96-well plates at a density of 1 000 cells per well. Replicate cultures (n ¼ 8) for each cell lines were plated. These cells were cultured for 5 days and their proliferation determined by a CellTiter assay (Promega) on days 1, 3, and 5 according to the manufacturer's recommendation. The absorbance of the colorimetric assay was determined at a wavelength of 490 nm using a multichannel plate spectrophotometer (Biotek Instruments, Winooski, VT, USA). Each experiment was done at least three times with identical results.
Soft agar assay
RPMI medium (2 Â , Life Technologies, Inc.) supplemented with 10% fetal bovine serum, 1 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin B was mixed with an equal volume of 0.6% Noble Agar (Cellgro, Mediatech Inc.). A measure of 4 ml of this mixture was first laid down as a bottom layer per 60-mm Petri dish. For top layers, 50 000 cells were well dispersed in the same mixture and layered on top of the bottom agar. These cells were then allowed to grow for 4-6 weeks in a 371C tissue culture incubator supplied with 5% humidified CO2.
Fluorescence in situ hybridization
Chromosome spreads of trypsinized BT-474 and ZR-75-30 cells were prepared according to standard procedures including hypotonic treatment. Purified BAC DNA from BAC#58 was labeled with digoxigenin dUTP and BAC DNA from #62 was labeled with biotin dUTP by nick translation. Two labeled probes were combined as differentially labeled pairs and hybridized to metaphase chromosomes and interphase nuclei in a solution containing sheared human DNA, 50% formamide, 10% dextran sulfate, and 2 Â SSC. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated antidigoxigenin antibodies as well as avidin Texas red followed by counterstaining with DAPI.
Statistical analysis
The fold increase in cell numbers was analysed by a two-tailed paired t-test between the Pip4k2b expressing cells and the GFP expressing control cells. For CellTiter assays, means of absorbance at 490 nM7s.d. were compared between the Pip4k2b expressing cells and the GFP expressing control cells (n ¼ 8) at days 1, 3 and 5 using two-tailed unpaired t-test. A P-value of less than 0.05 is considered statistically significant. All analyses were performed with statistical software (StatView version 5.0.1; SAS Institute Inc., Cary, NC, USA).
